For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Published Date: 08 Dec 2023

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

Read Full News

Latest News

Hidden Body Fat Threatens Male Fertility

Higher body fat percentage, rather than BMI, is associated with reduced sperm count and disrupted reproductive hormone levels in men.

Robotic Surgery May Help Restore Urine Control in Women

A robot-assisted procedure placing an artificial urinary sphincter may help women with stress incontinence achieve little or no urine leakage.

Many Men With LUTS Could Be Candidates to Stop Alpha-Blocker Treatment

— Novel N-of-1 study design showed minimal treatment effect for 11 of 30 patients

Advancing Evidence-Based Care for Veterans With mHSPC: Pathways, Personalization, and Team-Based Strategies

Advancing Evidence-Based Care for Veterans With mHSPC: Pathways, Personalization, and Team-Based Strategies

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Latest News

Higher body fat percentage, rather than BMI, is associated with reduced sperm count and disrupted reproductive hormone levels in men.

A robot-assisted procedure placing an artificial urinary sphincter may help women with stress incontinence achieve little or no urine leakage.

— Novel N-of-1 study design showed minimal treatment effect for 11 of 30 patients

Advancing Evidence-Based Care for Veterans With mHSPC: Pathways, Personalization, and Team-Based Strategies

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

News All Time

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Study showed immediate improvement in symptoms after intentional retrieval of device at 6 months

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Patient in his 60s eventually developed sepsis

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

U.S. study supports findings from a global trial using an external control arm

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Significantly higher risk of sedative, opioid, cocaine abuse compared with no ED diagnosis

GLP-1 Drugs Linked to Significant Boost in Testosterone Levels for Men

Weight loss likely not the only reason for improvement, researcher says

Tibial Nerve Stimulation for Overactive Bladder Tied to Better Quality of Life

But main results from sham-controlled trial still outstanding

No Prostate Cancer Survival Benefit With More Extensive Lymph Node Assessment

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade disease

Stoking Sexual Arousal and Desire: GLP-1s, Nerve Stimulation, 'Scream Cream'

GLP-1 agonists not helpful, may be harmful whereas neural, topical strategies often useful

Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

Darolutamide offers "an option for preserving cognitive health" in advanced disease, expert says

The Blind Spot in Bladder Cancer Care: What Patients Don't Say

Patients and urologists are not always aligned on what the treatment experience will be like

In Search of Effective Treatment for Premature Ejaculation: 'I Really Have No Idea'

Lack of high-level evidence has hindered treatment development, but some patients do improve

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

Combination significantly improved disease-free survival in phase III trial

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

ADT plus apalutamide before and after surgery significantly improved metastasis-free survival

Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

FDA's 'Big Dick Energy!' Warning; UHC Retreats on Prior Auth; Nurses Beat Ebola

Health news and commentary gathered by MedPage Today staff

Combating Cancer-Related Fatigue: Yoga, Bupropion, Exercise Plus Methylphenidate

Significant improvement with yoga and the atypical antidepressant

Recommended News For You

Novel Mimetic Bispecific Antibody Superior to Standard Care in Hemophilia A

Researchers explore e-bikes for cancer recovery

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

FDA Advisors Split on Regimens for Breast, Prostate Cancers

Obesity linked to subsequent neoplasms in childhood cancer survivors

Recommended Articles For You

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies 

Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After  

Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth  

The Power of White Blood Cells: How They Help Keep Us Healthy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

1.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

2.

Bone Marrow Regeneration in Hematologic Recovery

3.

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies

4.

Iron Homeostasis Throughout the Female Lifespan

5.

Demystifying Lymphocytes: Everything You Need to Know 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

2.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot